Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 28, 1997

View Archived Issues

Company Profile: LeukoSite

Company Profile: Oxigene

AutoImmune: Q3 1997 highlights

Company Profile: Progenics

Negative phase II results for long-term risedronate in osteoporosis

The new frontier in medical research: prion diseases

Antiplatelet and antithrombotic effects of NSL-9403

MedImmune seeks FDA approval for psoriasis trials with MEDI-507

Immunex seeks FDA approval for generic paclitaxel injection

Neurocrine Biosciences: Q3 1997 highlights

Boehringer Ingelheim and Vion sign agreement for Promycin

Isis antisense compound enters phase II

New approvals for Menorest

Terrapin and Pharmagene enter drug screening alliance

Lilly prepares new benzothiophenes

Glutamate antagonists discovered at BASF

Bayer patents new antiatherosclerotic agents

Rabeprazole safe and effective for short-term treatment of GERD

Results of large dose-finding study on rizatriptan in migraine reported

Sankyo isolates natural products for BPH

Sankyo discloses agents for diabetes and related complications

Antileukemic effects described for vesnarinone

KRN-4884: mechanism of action of new KATP channel opener

Biological profile of the potent, selective dopamine D4 antagonist L-745870

Antiproliferative effects of new tyrosine kinase inhibitor CGP-53716

Toyama's antiplatelet agent progresses to clinical studies

Preliminary phase II results in for VRI's adjuvanted influenza vaccine

Rituximab launched in Switzerland

European approvals for RPR's Nasacort AQ

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 8, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 8, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...